Post Profile






Spark Therapeutics and Pfizer announce publication in The New England Journal of Medicine of Interim Data from phase 1/2 clinical trial of investigational gene therapy for Hemophilia B

(Ten Bridge Communications) Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B.
read more

share

Related Posts


Osiris Therapeutics Reports Interim Data For COPD Stem Cell Study

Health : Medical News Today

Therapeutics, Inc. (NASDAQ:OSIR) announced six-month interim data from a Phase II clinical trial evaluating Prochymal, the Company's proprietary formulation of adult mesenchymal stem cells, for the treatment of chronic obstructive p...

Landmark Gene Therapy Clinical Trial For Hemophilia B: Commentary And Podcast

Health : Medical News Today

A recent article in the New England Journal of Medicine showed that Factor IX gene therapy in patients with hemophilia B was able to convert severe hemophilia to moderate or even mild disease. In a timely commentary, Thierry VandenD...

Landmark CAR-T Cancer Study Published in the New England Journal of Medicine

Health : Newswise Medical News

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Health : Newswise Medical News

Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 data at year one for investigational voretigene neparvovec an investigational, potential one-time gene therapy candidate for the treatment of patients with vi...

Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 clinical trial data for investigational voretigene neparvovec

Health : EurekAlert: Health

(Ten Bridge Communications) Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced The Lancet, a highly ranked peer-reviewed journal,...

Comments


Copyright © 2016 Regator, LLC